Hematology NewsOfatumumab approved for extended treatment of CLL patients in complete or partial responseJanuary 19, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsVenetoclax gets 79% overall response rate in high-risk CLLJanuary 13, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIbrutinib response durable at 1 year in CLL patients who relapsed after allogeneic stem cell transplantsJanuary 13, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsNew agents effectively target CLL’s molecular AchillesDecember 18, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsAnti-BCL2, CD20 combo safe, effective in untreated CLLDecember 17, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsFDA gives nod to rapid-infusion bendamustine for CLLDecember 9, 2015CLLLymphoma & Plasma Cell Disorders
Hematology NewsASH: Idelalisib plus standard therapy boosts survival in relapsed CLLDecember 9, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsUpfront idelalisib carries high risk for acute liver toxicityDecember 8, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsASH: First-line ibrutinib beats standard chemo for CLL/SLL in older patientsDecember 7, 2015CLLLymphoma & Plasma Cell Disorders
Hematology NewsASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancersDecember 5, 2015ALLCLLTransfusion MedicineLeukemia, Myelodysplasia, Transplantation
Hematology NewsMedical Roundtable: The Changing Pharmacologic Treatment Landscape in Chronic Lymphocytic Leukemia October 20, 2015CLLFollicular Lymphoma
Hematology NewsFive epigenetic biomarkers define three CLL subgroupsOctober 13, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsIgA increase linked to fewer infections in CLL patients on ibrutinibOctober 8, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsMHM: Novel agents, combos show promise for relapsed/refractory CLLOctober 2, 2015CLLLeukemia, Myelodysplasia, Transplantation
Hematology NewsMHM: Novel agents, combos show promise for relapsed/refractory CLLOctober 2, 2015CLLLeukemia, Myelodysplasia, Transplantation
